The present invention describes compounds of formula (A) for use as Parkinson's disease modifying-agents, said formula (A). Surprisingly it has been found that the compounds of the invention can significantly reduce alpha-synuclein aggregation and stimulate the functional interaction between alpha-synuclein and Synapsin III.
本发明描述了用作帕
金森病修饰剂的化合物的
化学式(A)。令人惊讶的是发现,本发明的化合物能够显著减少α-突触核蛋白的聚集,并促进α-突触核蛋白与Synapsin III之间的功能相互作用。